MA50223A - Sels inhibiteurs de ferroportine - Google Patents

Sels inhibiteurs de ferroportine

Info

Publication number
MA50223A
MA50223A MA050223A MA50223A MA50223A MA 50223 A MA50223 A MA 50223A MA 050223 A MA050223 A MA 050223A MA 50223 A MA50223 A MA 50223A MA 50223 A MA50223 A MA 50223A
Authority
MA
Morocco
Prior art keywords
ferroportine
inhibitor salts
inhibitor
salts
ferroportine inhibitor
Prior art date
Application number
MA050223A
Other languages
English (en)
Inventor
Fritz Blatter
Michael Burgert
Giuseppe Lapadula
Collin D Morris
Erik Philipp
Stefan Reim
Original Assignee
Vifor Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vifor Int Ag filed Critical Vifor Int Ag
Publication of MA50223A publication Critical patent/MA50223A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA050223A 2017-04-18 2018-04-18 Sels inhibiteurs de ferroportine MA50223A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17166907 2017-04-18

Publications (1)

Publication Number Publication Date
MA50223A true MA50223A (fr) 2020-07-22

Family

ID=58549089

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050223A MA50223A (fr) 2017-04-18 2018-04-18 Sels inhibiteurs de ferroportine

Country Status (13)

Country Link
US (1) US11129820B2 (fr)
EP (1) EP3612528B1 (fr)
JP (1) JP7065115B2 (fr)
CN (1) CN110785417B (fr)
AU (1) AU2018253864B2 (fr)
BR (1) BR112019021800A2 (fr)
EA (1) EA201992144A1 (fr)
ES (1) ES3055044T3 (fr)
IL (1) IL269812A (fr)
JO (1) JOP20180036A1 (fr)
MA (1) MA50223A (fr)
TN (1) TN2019000281A1 (fr)
WO (1) WO2018192973A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11286243B2 (en) 2018-12-13 2022-03-29 Global Blood Therapeutics, Inc. Ferroportin inhibitors and methods of use
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
EP3999059A1 (fr) * 2019-07-19 2022-05-25 Vifor (International) Ag Inhibiteurs de la ferroportine destinés à être utilisés dans le traitement de la bêta-thalassémie dépendante des transfusions (tdt)
US20220323416A1 (en) 2019-07-19 2022-10-13 Vifor (International) Ag Ferroportin-Inhibitors For The Use In The Prevention And Treatment Of Kidney Injuries
WO2021018023A1 (fr) * 2019-08-01 2021-02-04 济南泰达领创医药技术有限公司 Modulateur du récepteur glp-1 à petites molécules
KR20220086563A (ko) * 2019-10-22 2022-06-23 비포르 (인터내셔날) 아게 페로포틴 억제제(vit-2763)를 사용한 겸상적혈구병을 치료하기 위한 방법 및 조성물
US11813257B2 (en) * 2020-01-09 2023-11-14 Disc Medicine, Inc. Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
CA3172806A1 (fr) 2020-03-24 2021-09-30 Stefan Reim Procede de production d'inhibiteurs de ferroportine
KR20230007441A (ko) 2020-04-28 2023-01-12 글로벌 블러드 테라퓨틱스, 인크. 페로포르틴 억제제로서의 시클로알킬 피리미딘
US20230226074A1 (en) 2020-04-28 2023-07-20 Global Blood Therapeutics, Inc. Methods of use for pyrimidines as ferroportin inhibitors
CA3181577A1 (fr) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Thienopyrimidines servant d'inhibiteurs de la ferroportine
MX2023008515A (es) * 2021-01-20 2023-07-27 Vifor Int Ag Inhibidores de ferroportina para su uso en el tratamiento de sindromes mielodisplasicos (smd).
KR20230169981A (ko) * 2021-03-12 2023-12-18 디스크 메디슨, 인크. 적혈구증가증을 치료하기 위한 조성물 및 방법
TW202304896A (zh) * 2021-04-22 2023-02-01 瑞士商威佛（國際）股份有限公司 經修飾的膜鐵運輸蛋白(ferroportin)抑制劑
CA3232329A1 (fr) 2021-09-21 2023-03-30 Wilm Buhr Inhibiteurs de ferroportine n-substitues
AU2023362497A1 (en) 2022-10-21 2025-04-24 Vifor (International) Ag Bicyclic ferroportin inhibitors
CN120981247A (zh) 2023-03-27 2025-11-18 赛伦斯治疗有限责任公司 用于干细胞移植的化合物和组合物
CN116173218B (zh) * 2023-04-28 2023-08-04 北京大学口腔医学院 蛋白转运抑制剂在制备用于治疗或缓解牙周炎的药物中的用途
KR20260028017A (ko) 2023-06-26 2026-03-03 비포르 (인터내셔날) 아게 유전성 혈색소침착증(hh)의 치료에 사용하기 위한 페로포틴-저해제
WO2025096992A1 (fr) * 2023-11-01 2025-05-08 Navinta, Llc Procédé d'isolement de dérisomaltose ferrique solide
WO2026041650A1 (fr) 2024-08-20 2026-02-26 Vifor (International) Ag Inhibiteurs de ferroportine destinés à être utilisés dans le traitement de la néphrite lupique

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB937878A (en) 1959-12-24 1963-09-25 Ciba Ltd N-[5-nitro-(2)-furfurylidene]-pyrazole-carboxylic acid hydrazides and process for their manufacture
MY129541A (en) 1996-06-25 2007-04-30 Novartis Ag Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
US5922761A (en) 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
AR009655A1 (es) 1996-12-10 2000-04-26 Novartis Ag Una composicion parenteralmente inyectable, un metodo para su preparacion, metodos para el tratamiento de enfermedades, una modificacion decristal de 1-decansulfonato de desferrioxamina, su uso, un proceso para la produccion de dicha modificacion de cristal y una preparacion farmaceutica que
EP0946587A2 (fr) 1996-12-16 1999-10-06 Fujisawa Pharmaceutical Co., Ltd. Nouveaux composes amide
EP1169311A4 (fr) 1999-03-22 2004-09-15 Rhode Island Education Banques combinatoires d'oxazole et de thiazole
EP1072265A1 (fr) 1999-07-20 2001-01-31 MEDIS S.r.l. Medical Infusion Systems Utilisation de polyphenols des plantes pour le traitement de la surcharge en fer
EP1074254A3 (fr) 1999-07-20 2002-09-11 MEDIS S.r.l. Medical Infusion Systems Utilisation de polyphenols végétaux avec des vitamines pour le traitement de la surcharge en fer
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60137435D1 (de) 2000-09-15 2009-03-05 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
DE10063173A1 (de) 2000-12-18 2002-06-20 Merck Patent Gmbh Harnstoff- und Urethanderivate
AU2002356525A1 (en) 2001-09-24 2003-04-07 Elan Pharmaceuticals, Inc. Substituted amines for the treatment of neurological disorders
US20030109548A1 (en) 2001-11-09 2003-06-12 Royt Paulette W. Compositions and methods of treating iron excess
US6933308B2 (en) 2002-12-20 2005-08-23 Bristol-Myers Squibb Company Aminoalkyl thiazole derivatives as KCNQ modulators
SI1656139T1 (sl) 2003-07-21 2011-12-30 Merck Serono Sa Aril dikarboksamidi
WO2005014576A1 (fr) 2003-08-12 2005-02-17 Takeda Pharmaceutical Company Limited Derive d'isoquinoline, procede permettant de produire ce derive, et utilisation de ce derive
DE10356409B4 (de) 2003-11-28 2006-12-28 Biofrontera Discovery Gmbh Neues Arzneimittel Oxachelin und Derivate
FR2870271B1 (fr) 2004-05-11 2008-03-14 Bruno Merand Procede de construction d'une maison en bois et moyens pour la mise en oeuvre du procede.
WO2006040646A1 (fr) 2004-10-14 2006-04-20 Pfizer, Inc. Amides de benzimidazole ou d'indole en tant qu'inhibiteurs de pin1
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
US20060252807A1 (en) 2005-04-22 2006-11-09 Kalypsys, Inc. Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2006127550A1 (fr) 2005-05-23 2006-11-30 Merck & Co., Inc. Antagonistes des recepteurs d'orexine a base de bis-amide de proline
KR100970294B1 (ko) 2005-06-08 2010-07-15 니뽄 다바코 산교 가부시키가이샤 복소환 화합물
CN101287728A (zh) 2005-08-17 2008-10-15 先灵公司 新的高亲和力噻吩基和呋喃基激酶配体
US8324265B2 (en) 2005-11-21 2012-12-04 Shionogi & Co., Ltd. Heterocyclic compounds having type I 11β hydroxysteroid dehydrogenase inhibitory activity
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JP2009525955A (ja) 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CN101611007A (zh) 2006-12-20 2009-12-23 先灵公司 新颖的jnk抑制剂
AR065628A1 (es) 2007-03-07 2009-06-17 Xenon Pharmaceuticals Inc Compuestos triciclicos de utilidad en el tratamiento de trastornos por carencia de hierro en el organismo
AR065785A1 (es) 2007-03-19 2009-07-01 Xenon Pharmaceuticals Inc Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro
CN101646686A (zh) 2007-03-20 2010-02-10 明治制果株式会社 铁过剩症的预防或治疗剂
CL2008000793A1 (es) 2007-03-23 2008-05-30 Xenon Pharmaceuticals Inc Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro.
EP2133339A4 (fr) 2007-03-28 2010-04-21 Santen Pharmaceutical Co Ltd Nouveau dérivé de (2-aminophényl)pyridinecarboxamide ayant une structure d'urée
WO2008151288A2 (fr) 2007-06-05 2008-12-11 Xenon Pharmaceuticals Inc. Composés aromatiques et hétéroaromatiques utiles dans le traitement de troubles du métabolisme du fer
EP2303275A4 (fr) 2008-06-17 2012-05-09 Univ Duke Modulateurs du récepteur smoothened
TW201803586A (zh) 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8623859B2 (en) 2008-08-22 2014-01-07 Evotec Ag Bradykinin B1 antagonists
NZ591115A (en) 2008-09-26 2012-10-26 Boehringer Ingelheim Int Azaindazole compounds as ccr1 receptor antagonists
CA2743134A1 (fr) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Composes utiles comme inhibiteurs de l'atr kinase
US20110224136A1 (en) 2008-11-19 2011-09-15 Ting Pauline C Inhibitors of diacylglycerol acyltransferase
JP2012514044A (ja) 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR078278A1 (es) * 2009-09-09 2011-10-26 Vifor Int Ag Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
WO2013067578A1 (fr) 2011-11-07 2013-05-16 The University Of Queensland Modulateurs des récepteurs c3a
BR112014013697A2 (pt) 2011-12-09 2020-11-03 The Regents Of The University Of California peptídeos mini-hepcidina modificados e métodos de uso dos mesmos
EP2620142A1 (fr) 2012-01-27 2013-07-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Chemin de signalisation Hedgehog impliqué dans le métabolisme énergétique
EP2827853A1 (fr) 2012-03-22 2015-01-28 Nanotherapeutics, Inc. Compositions et procédés pour l'administration par voie orale de particules de diéthylènetriaminepentaacétate encapsulées
PE20150224A1 (es) 2012-05-11 2015-03-08 Abbvie Inc Inhibidores del nampt
CN103508957B (zh) 2012-06-25 2017-02-08 中国科学院上海药物研究所 羟乙基吡唑类化合物或氨乙基吡唑类化合物及其制备方法和用途
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
WO2015051362A1 (fr) 2013-10-04 2015-04-09 Illinois Institute Of Technology Chélateurs multifonctionnels, complexes, et compositions de ceux-ci, et leurs procédés d'utilisation
WO2015069660A2 (fr) 2013-11-05 2015-05-14 New York Blood Center, Inc. Procédés et compositions permettant de renforcer l'expression de l'hepcidine et faisant appel à de la transferrine liant/libérant le fer modifiée
CA2930966A1 (fr) 2013-11-22 2015-05-28 University Of Florida Research Foundation, Inc. Analogues de la desferrithiocine et leurs utilisations
UA123219C2 (uk) 2015-10-23 2021-03-03 Віфор (Інтернаціональ) Аґ Інгібітори феропортину

Also Published As

Publication number Publication date
AU2018253864A1 (en) 2019-10-03
AU2018253864B2 (en) 2021-08-19
JOP20180036A1 (ar) 2019-01-30
JP7065115B2 (ja) 2022-05-11
US11129820B2 (en) 2021-09-28
EP3612528A1 (fr) 2020-02-26
CN110785417A (zh) 2020-02-11
BR112019021800A2 (pt) 2020-05-05
TN2019000281A1 (en) 2021-05-07
EP3612528C0 (fr) 2025-11-19
EP3612528B1 (fr) 2025-11-19
CN110785417B (zh) 2023-05-23
IL269812A (en) 2019-11-28
WO2018192973A1 (fr) 2018-10-25
US20200113885A1 (en) 2020-04-16
EA201992144A1 (ru) 2020-03-17
JP2020516620A (ja) 2020-06-11
ES3055044T3 (en) 2026-02-09
CA3059533A1 (fr) 2018-10-25

Similar Documents

Publication Publication Date Title
MA50223A (fr) Sels inhibiteurs de ferroportine
CY1125826T1 (el) Ενωσεις αναστολεις της βητα-λακταμασης
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
IL269196A (en) Novel inhibitors
EP3541932A4 (fr) Inhibiteurs de crispr-cas9
MA42606A (fr) Sels d'un inhibiteur de lsd1
EP3801503A4 (fr) Inhibiteurs de sarm1
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3442972T3 (da) Bromdomænehæmmere
MA47573A (fr) Inhibiteurs de dihydrobenzofurane glycosidase substitués
LT3303334T (lt) Tirozinkinazės inhibitoriai
MA52813A (fr) Inhibiteurs de sarm1
EP3313828A4 (fr) Inhibiteurs de métallo-bêta-lactamases
DK3668955T3 (da) Korrosionsinhibitor
EP3817736A4 (fr) Inhibiteurs de pikfyve
EP3801499A4 (fr) Inhibiteurs de sarm1
EP3706747A4 (fr) Inhibiteurs de prmt5
EP3383883A4 (fr) Sels de conjugués en cancéro-thérapie
DK3630744T3 (da) Pyrazol-magl-inhibitorer
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
MA46889A (fr) Inhibiteurs de gsk-3
EP3706742A4 (fr) Inhibiteurs de prmt5
EP3600301A4 (fr) Inhibiteurs de kdm4
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase